Results 191 to 200 of about 6,027,899 (340)

Environmental impact of antidepressants: Is a new prescription framework possible?

British Journal of Clinical Pharmacology, EarlyView.
Aims Antidepressants such as venlafaxine and sertraline pose high risks to water ecosystems. As depressive disorders and other mental health conditions become increasingly prevalent worldwide, prescription and environmental presence of these pharmaceuticals continue to rise. This study explores the practical viability of a new framework for prescribing
Matilde Bianconi, Valentina Giunchi, Michael Thiede, Elisa Sangiorgi, Marco Menchetti, Elisabetta Poluzzi   +5 more
wiley   +1 more source

Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector. [PDF]

Mar Drugs
Teixeira LM, Reis CP, Pacheco R.
europepmc   +1 more source

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending [PDF]

EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S.
John A. Vernon, Joseph H. Golec
core  

Warfarin time in therapeutic range of primary healthcare patients in the Western Cape Province, South Africa

British Journal of Clinical Pharmacology, EarlyView.
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker, Christopher Kelly, Robin Dyers, Eric Decloedt   +3 more
wiley   +1 more source

Engagement of the private pharmaceutical sector for TB control: rhetoric or reality? [PDF]

J Pharm Policy Pract, 2017
Konduri N, Delmotte E, Rutta E.
europepmc   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Soft Skills, Strong Results: The Impact on Medical Representatives in the Saudi Pharmaceutical Sector. [PDF]

J Res Pharm Pract
Qashlan M, Halawany K, Ali M, Ahmad O, Halawani Z.   +4 more
europepmc   +1 more source

Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions. [PDF]

Int J Environ Res Public Health, 2017
Barbieri E, Huang M, Pi S, Tassinari M.
europepmc   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

British Journal of Clinical Pharmacology, EarlyView.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke, Emile Malan, Michael Reid, Patrick Bouic, Haylene Nell, Goonaseelan Pillai, Catriona Waitt, Bernd Rosenkranz   +7 more
wiley   +1 more source

Therapeutic approach of carbon nanotube: Revolutionize nanomaterial in biomedical and pharmaceutical sector. [PDF]

J Food Drug Anal
Ghosh S, Dave V, Wal P.
europepmc   +1 more source